Cytos Biotechnology updates phase II b trial of CYT003 in allergic asthma
News | 17 January 2013
Cytos Biotechnology Ltd, a public biopharmaceutical company focused on the development of targeted immunotherapies, has provided an update on the phase II b clinical trial with its lead product candidate, CYT003, in allergic asthma. The clinical trial ...
Click on the link to read the full article at pharmabiz.com
(This link will open in a new window)
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
